13 maart 2012: Nederlandse onderzoekers hebben in een studie bij 64 patiënten aangetoond dat Aldarazalf - imiquimod zalf vooraf aan een zogeheten MOH's operatie voor huidkanker in het gezicht uitstekend kan werken en de te verwijderen tumoren kleiner kan maken met hopelijk dan betere cosmetische resultaten. De zalf geeft bijna geen littekens na gebruik en volgens de inforamtie die daarover beschikbaar is heeft deze zalf ook immuunstimulerende kwaliteiten. Bij de helft van de deelnemende patiënten was de tumor voor 50 % of meer afgenomen. Hier het abstract van deze studie uitgevoerd in het Erasmus Medisch Centrum. Daaronder informatie over imiquimod zalf uit 2002, maar met zelfde uitstekende resultaten als nu in Rotterdam is aangetoond. Als u hier klikt vindt u informatie van het VUMC over Aldarazalf in een PDF. Als u hier klikt komt u op een website van een bedrijf dat Aldarazalf  verkoopt met ook veel informatie hoe en waarvoor Aldarazalkf is te gebruiken. Aldarazalf is officieel goedgekeurd als middel tegen o.a. huidkanker en wratten.

Br J Dermatol. 2012 Mar 3. doi: 10.1111/j.1365-2133.2012.10924.x. [Epub ahead of print]

Imiquimod 5% Cream as Pre-Treatment of Mohs Micrographic Surgery for Nodular Basal Cell Carcinoma in the Face, A Prospective Randomized Controlled Study Imiquimod As Pre-Treatment of Mohs.

Source

Department of Dermatology, Catharina Hospital Eindhoven, the Netherlands. Department of Dermatology, Erasmus MC Rotterdam, the Netherlands.

Abstract

Background:  Imiquimod 5% cream can reduce or clear superficial and small nodular basal cell carcinoma (BCC). It could be used as a pre-treatment of Mohs micrographic surgery (MMS) to decrease defect size. Objective:  To study if a pre-treatment with imiquimod 5% cream decreases defect size after Mohs micrographic surgery. In addition, to study the effect on the number of Mohs stages and reconstruction time. Methods and Materials:  Seventy patients >18 years with a primary nodular BCC in the face were included. The imiquimod group used imiquimod 5% cream for 4 weeks, before MMS. The control group was treated with MMS only. Tumour and defect sizes were measured. We noted the number of Mohs-stages, reconstruction time and side-effects. Results:  The median percentage increase in area from tumour size at baseline to the post-MMS defect for the imiquimod group was significantly less compared to the control group, 50% vs 147% (p=0.00). A tendency towards less Mohs stages in the imiquimod group was observed and the reconstruction time was significantly shorter in this group (0.01)

Conclusion:  Imiquimod 5% cream as pre-treatment of MMS significantly reduced the tumour size in a primary nodular BCC and reduced the surgical defect size. Further research is necessary to investigate cost-effectiveness.

Copyright © 2012 British Association of Dermatologists.

PMID:
22385074
[PubMed - as supplied by publisher]

Het bedrijf 3M Co. meldt dat zij in fase III trials een zalf hebben ontwikkeld die wratten en beginnende huidkanker binnen enkele weken kan wegnemen. Nu is basecell kanker niet direct dodelijk en kan wel genezen met bv. PDT - Photodynamische therapie - lichttherapie, maar toch is deze studie wel van belang gezien het gemak waarmee de zalf kan worden aangebracht en volgens de onderzoekers de geringe littekens die je eraan overhoudt. Bovendien wordt aangetoond in studies dat de zalf ook een immunologisch proces op gang brengt. Dit persbericht stond op Reuters:

By Ransdell Pierson 

NEW YORK (Reuters) - A cream used to treat genital warts has proved successful in clearing up pre-cancerous skin lesions and common small skin tumors that now typically require surgical removal, the drug's maker, 3M Co., said on Monday. 

If regulators approve the drug, Aldara, for this additional treatment, it could reduce the need for widely performed surgical procedures to remove or burn away such skin growths caused by excessive sun exposure -- among the most common reasons for visits to 
dermatologists. Aldara, which was approved in the United States in 1997 to treat genital warts, now generates annual revenues of more than $100 million. But 3M officials have predicted that sales of the cream could balloon by up to an additional $600 million if it is eventually approved for the types of lesions and skin tumors that it successfully treated in the late-stage Phase III trials. 

The trial results came days after 3M disclosed that one of its other drugs, an experimental antiviral cream called Resiquimod, failed in late-stage trials against genital herpes. 
Aldara and Resiquimod are among a class of medicines discovered by 3M known as immune response modifiers, which are believed to stimulate the body's immune system to fight viral infections and other diseases -- including skin cancers. 

3M on Monday said Aldara proved highly successful in Phase III trials against actinic keratoses, slightly raised lesions on the skin that can develop into skin cancer, and against common small skin tumors called superficial basal cell carcinomas that can disfigure patients but are rarely fatal. 

In two trials involving 436 patients with numerous actinic keratoses, patients were treated either with Aldara or a placebo cream twice a week for 16 weeks. After eight weeks, the average patient treated with Aldara saw the number of lesions reduced by 83 percent -- compared with no reduction in the placebo group. Clearance of all lesions was seen in 45 percent of patients receiving the 3M cream, versus only 3 percent in the placebo group. 


"Some patients come into my office with 100 or more (actinic keratoses) lesions and I have to ask myself how I'm going to remove all of them," said Dr. Mark Lebwohl, a dermatologist at Mt. Sinai Hospital in New York, who helped conduct the Aldara trials for treating such lesions. "But with Aldara, the patient just puts the cream on and gets rid of the majority of them. Then the dermatologist can much more easily destroy the few that remain, by burning or freezing them," said Lebwohl, who acknowledged having financial ties to 3M. 

Lebwohl said freezing and burning techniques can leave noticeable scars and white spots, whereas the marks left with Aldara are "minor and transient." 

In two other trials involving 724 patients with superficial basal cell carcinomas, patients were also given either Aldara or a placebo cream. The average patient using Aldara five times a week for six weeks saw the number of tumors reduced by 82 percent, compared with 3 
percent of those using placebos. Aldara's most commonly reported side effects were skin reactions such as itching and burning or flaking and scaling, 3M said. 


Plaats een reactie ...

Reageer op "Aldarazalf - Imiquimod gebruikt vooraf aan MOH operatie bij huidkanker in het gezicht geeft uitstekende resultaten, aldus Nederlandse studie."


Gerelateerde artikelen